Bayer’s Nubeqa, en route to blockbusterland, clinches 2nd win in prostate cancer subtype
Fierce Pharma
JULY 17, 2024
Bayer has claimed a second pivotal trial win for its blockbuster-to-be androgen receptor inhibitor Nubeqa, looking to reach the entire space of metastatic hormone-sensitive prostate cancer (mHSPC). | Bayer has claimed a second pivotal trial win for its blockbuster-to-be androgen receptor inhibitor Nubeqa, looking to reach the entire space of metastatic hormone-sensitive prostate cancer.
Let's personalize your content